Gonadis national registry on gonadal status in pituitary and adrenal disorders: prevalence and characterization of sexual dysfunctions in male patients with acromegaly

Francesco Garifalos; Tiziana Feola; Noemi Fralassi; Angelis Cristina De; Marianna Minnetti; Rosa Pirchio; Linda Vignozzi; Annamaria Colao; Giovanni Corona; Andrea Isidori; Rosario Pivonello

doi:10.1530/endoabs.99.EP1250

EP1250

Prev Next

Section Contents Cite

Endocrine Abstracts (2024) 99 EP1250 | DOI: 10.1530/endoabs.99.EP1250

ECE2024 Eposter Presentations Late Breaking (127 abstracts)

Gonadis national registry on gonadal status in pituitary and adrenal disorders: prevalence and characterization of sexual dysfunctions in male patients with acromegaly

Francesco Garifalos ¹ , Tiziana Feola ² , Noemi Fralassi ³ , Cristina De Angelis ¹ , Marianna Minnetti ² , Rosa Pirchio ¹ , Linda Vignozzi ³ , Annamaria Colao ¹ , Giovanni Corona ⁴ , Andrea Isidori ² & Rosario Pivonello ¹

Err

Author affiliations

¹Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, Diabetologia ed Andrologia, Unità di Andrologia e Medicina della Riproduzione, Sessualità e Affermazione di Genere (FERTISEXCARES), naples; ²Dipartimento di Medicina Sperimentale, rome; ³Dipartimento di Scienze Sperimentali Cliniche e Biomediche “Mario Serio”, florence; ⁴Endocrinology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy - Department of Clinical Sciences and Community Health, bologna

The potential independent role of growth hormone (GH) excess in sexual dysfunction of acromegalic male patients is poorly characterized. The aim of the current study was to evaluate the sexual function, in adult males with acromegaly, stratifying the cohort in “uncontrolled” and “controlled” disease. Data were retrieved from GONADIS, a national registry on gonadal status and reproductive and psycho-sexual function in patients affected by pituitary and adrenal disorders, promoted by SIAMS - SIE - AME. Sixty male acromegalic patients aged 18-73 yrs (mean age: 51.4 ±13.4 yrs) were evaluated. In the overall cohort, 34/60 (56.6%) patients had reached disease control; 10/23 (43.4%) had ED at IIEF, 26/34 (76.4%) BPH, 17/37 (45.9%) varicocele, 7/37 (18.9%) testis hypotrophy, 17/47 (36.1%) hypotestosteronemia. Controlled disease patients had significantly higher age (P=0.021), disease duration (P=0.003), IIEF-15 total score (P=0.011), IIEF-erectile function (IIEF-EF) (P=0.008), IIEF-orgasmic function (IIEF-OF) (P=0.021), IIEF-Sexual desire (IIEF-SD) (P=0.006) and IIEF-Overall satisfaction (IIEF-OS) (P=0.012), and lower serum levels of insulin (P=0.022), HOMA index (P=0.046), glycated hemoglobin (P=0.013), IGF-1 (P<0.001) and GH (P<0.001). Controlled disease patients had a lower prevalence of ED (P=0.001). Correlation analysis in overall cohort highlighted that IIEF-EF score negatively correlated with free anxiety (MHQ-A) (r=-0.470; P=0.015) and depression (MHQ-D) (r=-0.503; P=0.009) traits, serum IGF-1 levels (r=-0.308; P=0.025); IIEF-OF (r=-0.460; P=0.031), IIEF-SD (r=-0.542; P=0.009) and IIEF-OS (r=-0.515; P=0.014) scores negatively correlated with serum IGF-1 levels. SIEDY scale 1 score correlated positively with age (r=0.386; P=0.02) and negatively with Peak Systolic Velocity at penile-US (r=-0.423; P=0.016). Linear regression analysis with age, testosterone, IGF-1, MHQ-A and MHQ-D scores as independent variables failed to identify a main independent predictor of IIEF-EF score.